

biologics/biologics-guidances, or <https://www.regulations.gov>.

Dated: October 2, 2020.

**Lauren K. Roth,**

*Acting Principal Associate Commissioner for Policy.*

[FR Doc. 2020-22228 Filed 10-7-20; 8:45 am]

**BILLING CODE 4164-01-P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Health Resources and Services Administration

#### Senior Executive Service Performance Review Board

**AGENCY:** Health Resources and Services Administration (HRSA), Department of Health and Human Services (HHS).

**ACTION:** Notice.

**SUMMARY:** HRSA, an operating division of HHS, is publishing a list of persons who may be named to serve on the Performance Review Board that oversees the evaluation of performance appraisals for Senior Executive Service members within HRSA for the Fiscal Year 2021 and 2022 review period.

#### FOR FURTHER INFORMATION CONTACT:

Georgia Lyons, HRSA, Executive Resources, Office of Human Resources, 5600 Fishers Lane, Rm 12N06C, Rockville, Maryland 20857, or (301) 443-4618.

**SUPPLEMENTARY INFORMATION:** Title 5, U.S.C. Section 4314(c)(4) of the Civil Service Reform Act of 1978, Public Law 95-454, requires that the appointment of Performance Review Board Members be published in the **Federal Register**. The following persons may be named to serve on the HRSA Performance Review Board:

Onyekachukwu Anaedozie  
Leslie Atkinson  
Cynthia Baugh  
Tonya Bowers  
Adriane Burton  
Tina Cheatham  
Laura Cheever  
Natasha Coulouris  
Cheryl Dammons  
Elizabeth DeVoss  
Diana Espinosa  
Catherine Ganey  
Alexandra Garcia  
Heather Hauck  
Laura Kavanagh  
Martin Kramer  
Torey Mack  
James Macrae  
Susan Monarez  
Thomas Morris  
Luis Padilla  
Wendy Ponton

Michael Warren

**Thomas J. Engels,**  
*Administrator.*

[FR Doc. 2020-22276 Filed 10-7-20; 8:45 am]

**BILLING CODE 4165-15-P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Health Resources and Services Administration

#### Meeting on the Advisory Commission on Childhood Vaccines; Correction

**AGENCY:** Health Resources and Services Administration (HRSA), Department of Health and Human Services (HHS).

**ACTION:** Notice; correction.

**SUMMARY:** The original **Federal Register** Notice announcing the December 2020 Advisory Commission on Childhood Vaccines (ACCV) meeting indicated that this meeting would be held on December 3, 2020, and December 4, 2020. This meeting is not being conducted over two days, and instead will only take place on December 3, 2020.

#### FOR FURTHER INFORMATION CONTACT:

Annie Herzog, Program Analyst, Division of Injury Compensation Programs (DICP), HRSA, in one of three ways: (1) Send a request to the following address: Annie Herzog, Program Analyst, DICP, HRSA, 5600 Fishers Lane, 08N186B, Rockville, Maryland 20857; (2) call (301) 443-6593; or (3) send an email to [ACCV@hrsa.gov](mailto:ACCV@hrsa.gov).

**SUPPLEMENTARY INFORMATION:** The ACCV will hold a public meeting on December 3, 2020, at 10:00 a.m. Eastern Time. The meeting will be held via Adobe Connect and telephone conference. The public can join the meeting by:

1. (Audio Portion) Calling the conference phone number 888-790-1734 and providing the following information:

*Leader Name:* Ms. Tamara Overby.  
*Passcode:* 4177683.

2. (Visual Portion) Connecting to the ACCV Adobe Connect Meeting using the following URL: <https://hrsa.connectsolutions.com/accv/>. Participants should call and connect 15 minutes prior to the meeting in order for logistics to be set up. If you have never attended an Adobe Connect meeting, please test your connection using the following URL: [https://hrsa.connectsolutions.com/common/help/en/support/meeting\\_test.htm](https://hrsa.connectsolutions.com/common/help/en/support/meeting_test.htm) and get a quick overview by following URL: [http://www.adobe.com/go/connectpro\\_overview](http://www.adobe.com/go/connectpro_overview).

Meeting times could change. For the latest information regarding the meeting, including start time and the agenda, please access the ACCV website: <http://www.hrsa.gov/advisorycommittees/childhoodvaccines/index.html>.

*This meeting will only take place on December 3, 2020, and is not being conducted over 2 days (December 3-4, 2020), as stated previously in **Federal Register** notice 2019-28294 (85 FR 112, published on January 2, 2020, page 112-113).*

**Maria G. Button,**

*Director, Executive Secretariat.*

[FR Doc. 2020-22209 Filed 10-7-20; 8:45 am]

**BILLING CODE 4165-15-P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### Proposed Collection; 60-Day Comment Request; Cancer Therapy Evaluation Program (CTEP) Branch and Support Contracts Forms and Surveys (National Cancer Institute)

**AGENCY:** National Institutes of Health, HHS.

**ACTION:** Notice.

**SUMMARY:** In compliance with the requirement of the Paperwork Reduction Act of 1995 to provide opportunity for public comment on proposed data collection projects, the National Cancer Institute (NCI) will publish periodic summaries of proposed projects to be submitted to the Office of Management and Budget (OMB) for review and approval.

**DATES:** Comments regarding this information collection are best assured of having their full effect if received within 60 days of the date of this publication.

**FOR FURTHER INFORMATION CONTACT:** To obtain a copy of the data collection plans and instruments, submit comments in writing, or request more information on the proposed project, contact: Michael Montello, Pharm. D., Cancer Therapy Evaluation Program (CTEP), 9609 Medical Center Drive, MSC 9742, Rockville, MD 20850 or call non-toll-free number 240-276-6080 or email your request, including your address to: [montellom@mail.nih.gov](mailto:montellom@mail.nih.gov). Formal requests for additional plans and instruments must be requested in writing.

**SUPPLEMENTARY INFORMATION:** Section 3506(c)(2)(A) of the Paperwork Reduction Act of 1995 requires: Written

comments and/or suggestions from the public and affected agencies are invited to address one or more of the following points: (1) Whether the proposed collection of information is necessary for the proper performance of the function of the agency, including whether the information will have practical utility; (2) The accuracy of the agency's estimate of the burden of the proposed collection of information, including the validity of the methodology and assumptions used; (3) Ways to enhance the quality, utility, and clarity of the information to be collected; and (4) Ways to minimize the burden of the collection of information on those who are to respond, including the use of appropriate automated, electronic, mechanical, or other technological collection techniques or other forms of information technology.

*Proposed Collection Title:* CTEP Support Contract Forms and Surveys (NCI), 0925–0753 Expiration Date 07/

31/2021, REVISION, National Cancer Institute (NCI), National Institutes of Health (NIH).

*Need and Use of Information Collection:* The National Cancer Institute (NCI) Cancer Therapy Evaluation Program (CTEP) and the Division of Cancer Prevention (DCP) fund an extensive national program of cancer research, sponsoring clinical trials in cancer prevention, symptom management and treatment for qualified clinical investigators. As part of this effort, CTEP implements programs to register clinical site investigators and clinical site staff, and to oversee the conduct of research at the clinical sites. CTEP and DCP also oversee two support programs, the NCI Central Institutional Review Board (CIRB) and the Cancer Trial Support Unit (CTSU). The combined systems and processes for initiating and managing clinical trials is termed the Clinical Oncology Research Enterprise (CORE) and represents an

integrated set of information systems and processes which support investigator registration, trial oversight, patient enrollment, and clinical data collection. The information collected is required to ensure compliance with applicable federal regulations governing the conduct of human subjects research (45 CFR 46 and 21 CFR 50), and when CTEP acts as the Investigational New Drug (IND) holder, FDA regulations pertaining to the sponsor of clinical trials and the selection of qualified investigators under 21 CFR 312.53). Survey collections assess satisfaction and provide feedback to guide improvements with processes and technology.

OMB approval is requested for 3 years. There are no costs to respondents other than their time. The total estimated annualized burden hours are 151,716.

#### ESTIMATED ANNUALIZED BURDEN HOURS

Form name	Type of respondent	Number of respondents	Number of responses per respondent	Average burden per response (in hours)	Total annual burden hours
CTSU IRB/Regulatory Approval Transmittal Form (Attach. A01).	Health Care Practitioner	2,444	12	2/60	978
CTSU IRB Certification Form (Attach. A02) .....	Health Care Practitioner	2,444	12	10/60	4,888
Withdrawal from Protocol Participation Form (Attach. A03).	Health Care Practitioner	279	1	10/60	47
Site Addition Form (Attach. A04) .....	Health Care Practitioner	80	12	10/60	160
CTSU Request for Clinical Brochure (Attach. A06).	Health Care Practitioner	360	1	10/60	60
CTSU Supply Request Form (Attach. A07) .....	Health Care Practitioner	90	12	10/60	180
RTOG 0834 CTSU Data Transmittal Form (Attach. A10).	Health Care Practitioner	12	76	10/60	152
CTSU Patient Enrollment Transmittal Form (Attach. A15).	Health Care Practitioner	12	12	10/60	24
CTSU Transfer Form (Attach. A16) .....	Health Care Practitioner	360	2	10/60	120
CTSU System Access Request Form (Attach. A17).	Health Care Practitioner	180	1	10/60	30
CTSU OPEN Rave Request Form (Attach. A18)	Health Care Practitioner	30	21	10/60	105
CTSU LPO Form Creation (Attach. A19) .....	Health Care Practitioner	5	2	120/60	20
CTSU Site Form Creation and PDF (Attach. A20)	Health Care Practitioner	400	10	30/60	2,000
CTSU PDF Signature Form (Attach. A21) .....	Health Care Practitioner	400	10	10/60	667
NCI CIRB AA & DOR between the NCI CIRB and Signatory Institution (Attach. B01).	Participants .....	50	1	15/60	13
NCI CIRB Signatory Enrollment Form (Attach. B02).	Participants .....	50	1	15/60	13
CIRB Board Member Application (Attach. B03) ...	Board Member .....	100	1	30/60	50
CIRB Member COI Screening Worksheet (Attach. B08).	Board Members .....	100	1	15/60	25
CIRB COI Screening for CIRB meetings (Attach. B09).	Board Members .....	72	1	15/60	18
CIRB IR Application (Attach. B10) .....	Health Care Practitioner	80	1	1	80
CIRB IR Application for Exempt Studies (Attach. B11).	Health Care Practitioner	4	1	30/60	2
CIRB Amendment Review Application (Attach. B12).	Health Care Practitioner	400	1	15/60	100
CIRB Ancillary Studies Application (Attach. B13)	Health Care Practitioner	1	1	1	1
CIRB Continuing Review Application (Attach. B14).	Health Care Practitioner	400	1	15/60	100
Adult IR of Cooperative Group Protocol (Attach. B15).	Board Members .....	65	1	180/60	195
Pediatric IR of Cooperative Group Protocol (Attach. B16).	Board Members .....	15	1	180/60	45

## ESTIMATED ANNUALIZED BURDEN HOURS—Continued

Form name	Type of respondent	Number of respondents	Number of responses per respondent	Average burden per response (in hours)	Total annual burden hours
NCI Adult/Pediatric Continuing Review of Cooperative Group Protocol (Attach. B17).	Board Members .....	275	1	1	275
Adult Amendment of Cooperative Group Protocol (Attach. B19).	Board Members .....	40	1	120/60	80
Pediatric Amendment of Cooperative Group Protocol (Attach. B20).	Board Members .....	25	1	120/60	50
Pharmacist's Review of a Cooperative Group Study (Attach. B21).	Board Members .....	50	1	120/60	100
Adult Expedited Amendment Review (Attach. B23).	Board Members .....	348	1	30/60	174
Pediatric Expedited Amendment Review (Attach. B24).	Board Members .....	140	1	30/60	70
Adult Expedited Continuing Review (Attach. B25)	Board Members .....	140	1	30/60	70
Pediatric Expedited Continuing Review (Attach. B26).	Board Members .....	36	1	30/60	18
Adult Cooperative Group Response to CIRB Review (Attach. B27).	Health Care Practitioner	30	1	1	30
Pediatric Cooperative Group Response to CIRB Review (Attach. B28).	Health Care Practitioner	5	1	1	5
Adult Expedited Study Chair Response to Required Modifications (Attach. B29).	Board Members .....	40	1	30/60	20
Reviewer Worksheet- Determination of UP or SCN (Attach. B31).	Board Members .....	400	1	10/60	67
Reviewer Worksheet -CIRB Statistical Reviewer Form (Attach. B32).	Board Members .....	100	1	15/60	25
CIRB Application for Translated Documents (Attach. B33).	Health Care Practitioner	100	1	30/60	50
Reviewer Worksheet of Translated Documents (Attach. B34).	Board Members .....	100	1	15/60	25
Reviewer Worksheet of Recruitment Material (Attach. B35).	Board Members .....	20	1	15/60	5
Reviewer Worksheet Expedited Study Closure Review (Attach. B36).	Board Members .....	20	1	15/60	5
Reviewer Worksheet of Expedited IR (Attach. B38).	Board Members .....	5	1	30/60	3
Annual Signatory Institution Worksheet About Local Context (Attach. B40).	Health Care Practitioner	400	1	40/60	267
Annual Principal Investigator Worksheet About Local Context (Attach. B41).	Health Care Practitioner	1,800	1	20/60	600
Study-Specific Worksheet About Local Context (Attach. B42).	Health Care Practitioner	4,800	1	15/60	1,200
Study Closure or Transfer of Study Review Resp. (Attach. B43).	Health Care Practitioner	1,680	1	15/60	344
Unanticipated Problem or Serious or Continuing Noncompliance Reporting Form (Attach. B44).	Health Care Practitioner	360	1	20/60	120
Change of Signatory Institution PI Form (Attach. B45).	Health Care Practitioner	120	1	20/60	40
Request Waiver of Assent Form (Attach. B46) ....	Health Care Practitioner	35	1	20/60	12
CIRB Waiver of Consent Request Supplemental Form (Attachment B47).	Health Care Practitioner	20	1	15/60	5
Review Worksheet CIRB Review for Inclusion of Incarcerated Participants (Attachment B48).	Board Members .....	20	1	1	20
Notification of Incarcerated Participant Form (B49).	Health Care Practitioner	20	1	20/60	7
CTSU OPEN Survey (Attach. C03) .....	Health Care Practitioner	10	1	15/60	3
CIRB Customer Satisfaction Survey (Attach. C04).	Participants .....	600	1	15/60	150
Follow-up Survey (Communication Audit) (Attach. C05).	Participants/Board Members.	300	1	15/60	75
CIRB Board Member Annual Assessment Survey (Attach. C07).	Board Members .....	60	1	15/60	15
PIO Customer Satisfaction Survey (Attach. C08)	Health Care Practitioner	60	1	5/60	5
Audit Scheduling Form (Attach. D01) .....	Group/CTMS Users .....	152	5	21/60	266
Preliminary Audit Findings Form (Attach. D02) ....	Auditor .....	152	5	10/60	127
Audit Maintenance Form (Attach. D03) .....	Group/CTMS Users .....	152	5	9/60	114
Final Audit Finding Report Form (Attach. D04) ....	Group/CTMS Users .....	75	11	1,098/60	15,098
Follow-up Form (Attach. D05) .....	Group/CTMS Users .....	75	7	27/60	236
Roster Maintenance Form (Attach. D06) .....	CTMS Users .....	5	1	18/60	2

## ESTIMATED ANNUALIZED BURDEN HOURS—Continued

Form name	Type of respondent	Number of respondents	Number of responses per respondent	Average burden per response (in hours)	Total annual burden hours
Final Report and CAPA Request Form (Attach. D07).	CTMS Users .....	12	9	1,800/60	3,240
NCI/DCTD/CTEP FDA Form 1572 for Annual Submission (Attach. E01).	Physician .....	26,500	1	15/60	6,625
NCI/DCTD/CTE Biosketch (Attach. E02) .....	Physician; Health Care Practitioner.	48,000	1	120/60	96,000
NCI/DCTD/CTEP Financial Disclosure Form (Attach. E03).	Physician; Health Care Practitioner.	48,000	1	15/60	12,000
NCI/DCTD/CTEP Agent Shipment Form (ASF) (Attach. E04).	Physician .....	24,000	1	10/60	4,000
Totals .....	.....	167,715	276	.....	151,716

Dated: October 1, 2020.

**Diane Kreinbrink,**

*Project Clearance Liaison, National Cancer Institute, National Institutes of Health.*

[FR Doc. 2020-22265 Filed 10-7-20; 8:45 am]

**BILLING CODE 4140-01-P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### Center for Scientific Review; Notice of Closed Meetings

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meetings.

The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

*Name of Committee:* Digestive, Kidney and Urological Systems Integrated Review Group; Systemic Injury by Environmental Exposure.

*Date:* November 5–6, 2020.

*Time:* 9:00 a.m. to 6:00 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892 (Virtual Meeting).

*Contact Person:* Yunshang Piao, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institute of Health, 6701 Rockledge Drive, Room 6184, Bethesda, MD 20892, (301) 402-8402, [piaoy3@mail.nih.gov](mailto:piaoy3@mail.nih.gov).

*Name of Committee:* Center for Scientific Review Special Emphasis Panel;

Fellowships: Musculoskeletal, Rehabilitation and Skin Sciences.

*Date:* November 5–6, 2020.

*Time:* 9:00 a.m. to 11:00 a.m.

*Agenda:* To review and evaluate grant applications.

*Place:* National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892 (Virtual Meeting).

*Contact Person:* Chi-Wing Chow, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 4110, Bethesda, MD 20892, (301) 402-3912, [chowc2@mail.nih.gov](mailto:chowc2@mail.nih.gov).

*Name of Committee:* Center for Scientific Review Special Emphasis Panel;

Fellowships: Oncology.

*Date:* November 5–6, 2020.

*Time:* 9:00 a.m. to 5:00 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892 (Virtual Meeting).

*Contact Person:* Reigh-Yi Lin, Ph.D.; Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Rm. 4152, MSC 7846, Bethesda, MD 20892, (301) 827-6009, [lin.reigh-yi@nih.gov](mailto:lin.reigh-yi@nih.gov).

*Name of Committee:* Center for Scientific Review Special Emphasis Panel; Small Business: Renal and Urological Sciences.

*Date:* November 5, 2020.

*Time:* 9:00 a.m. to 6:00 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892 (Virtual Meeting).

*Contact Person:* Santanu Banerjee, Ph.D.; Scientific Review Officer, Center for Scientific Review, National Institute of Health, 6701 Rockledge Drive, Room 2106, Bethesda, MD 20892, (301) 496-0000, [banerjees5@mail.nih.gov](mailto:banerjees5@mail.nih.gov).

*Name of Committee:* Center for Scientific Review Special Emphasis Panel; Topics in Bacterial Pathogenesis.

*Date:* November 5, 2020.

*Time:* 9:30 a.m. to 6:00 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892 (Virtual Meeting).

*Contact Person:* Richard G Kostriken, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 3192, MSC 7808, Bethesda, MD 20892, 240-519-7808, [kostrikr@csr.nih.gov](mailto:kostrikr@csr.nih.gov).

*Name of Committee:* Center for Scientific Review Special Emphasis Panel; Member Conflict: Molecular Genetics, Genetic Variation, Genetic/Macromolecular Evolution and Prokaryotic Cell Biology.

*Date:* November 5, 2020.

*Time:* 11:00 a.m. to 3:00 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892 (Virtual Meeting).

*Contact Person:* Methode Bacanamwo, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 2200, Bethesda, MD 20892, 301-827-7088, [methode.bacanawmo@nih.gov](mailto:methode.bacanawmo@nih.gov).

*Name of Committee:* Center for Scientific Review Special Emphasis Panel RFA Panel: The Neuropathological Basis for Chemo Brain.

*Date:* November 5, 2020.

*Time:* 2:00 p.m. to 5:00 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892 (Virtual Meeting).

*Contact Person:* Wei-Qin Zhao, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 5181, MSC 7846, Bethesda, MD 20892-7846, 301-827-7238, [zhaow@csr.nih.gov](mailto:zhaow@csr.nih.gov).

(Catalogue of Federal Domestic Assistance Program Nos. 93.306, Comparative Medicine; 93.333, Clinical Research, 93.306, 93.333, 93.337, 93.393-93.396, 93.837-93.844, 93.846-93.878, 93.892, 93.893, National Institutes of Health, HHS)